A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
-
![]()
News Ribosomal Dysfunction as an Oncogenic Driver in Certain Leukemias
The team led by Guy Sauvageau, director of IRIC’s Molecular Genetics of Stem Cells Research Unit, has identified a subtype of acute myeloid leukemia (AML) characterized by a significant reduction in the cells’ ability to produce proteins resulting from the loss of several ribosomal genes. This study, which proposes a new conceptual model of leukemogenesis, paves the way for the identification of new biomarkers and a new therapeutic vulnerability. Led by Principal Research Advisor Jean-François Spinella, this work is published in the journal Science Advances.
-
![]()
News The winners of the 2026 IRIC Next Generation Competition are joining the Institute!
This summer, 12 students have the opportunity to complete a 12- or 16-week research internship at IRIC, in addition to receiving an excellence scholarship.
-
![]()
News Michel Bouvier Named Officer of the Order of Canada
Professor Michel Bouvier, director of IRIC’s Molecular Pharmacobiology Research Unit, has been named an Officer of the Order of Canada by the Governor General.
-
![]()
News 2026 Student Recruitment Event: Meet the scientific talents of tomorrow!
Each year, the IRIC Student Recruitment Event offers students interested in pursuing graduate studies in cancer research a unique opportunity to participate in an international recruitment event at the Institute for Research in Immunology and Cancer at the University of Montreal.
-
![]()
News More than $1 million in grant for Michel Bouvier and the startup Drave Therapeutics
The team of Michel Bouvier, director of IRIC’s Molecular Pharmacology Research Unit, receives $1,08 M for a project in precision pharmacology of G protein-coupled receptors (GPCR). This grant is supported by the Consortium québécois sur la découverte du médicament (CQDM), through the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec, and by the co-funding partners Drave Therapeutics and the Université de Montréal.
-
![]()
News Claude Perreault Named Knight of the Ordre national du Québec
On June 17, Professor Claude Perreault, director of IRIC’s Immunobiology Research Unit, will be awarded the title of Knight of the Ordre national du Québec.
Latest publications
See all publications-
June 18, 2026 Apelin analog treatment reverses severe pulmonary arterial hypertension and right ventricular heart failure.
Vu J, Zhabyeyev P, Brown KJ, Gorham JM, DeLaughter DM, Chen H, Jayawardena TU, Vergara A, Alexiou M, Wijewardane A, Fischer C, Avet C, Ewasiuk A, Wang F, Chappell MC, Kim Y, Bouvier M, Vederas JC, Seidman CE, Seidman JG, Oudit GY
JCI Insight 2026-06-18 ; - See all publications